an affiliate of
     
We Need Your help as a 50-State Network Advocate!
Now is your time to be heard
Join the 50-State Network here
The 50-State Network is a grassroots advocacy organization comprised of patients like you. We are working to share the patient perspective, which is crucial in the State and Federal health policy and regulatory arenas. Patients need a voice in all conversations that relate to our access to treatment, safety, or the quality of our care. This community is made up of patients living with diverse chronic illnesses, including rheumatoid arthritis, lupus, and psoriasis, and the people who care about them. The 50-State Network is about transforming pain into purpose, empowering those that may feel victimized by disease. Our focus is on repurposing the energy of frustration, despair, and helplessness into positive mobilization, action, and fair representation to benefit all of us. Our formula, which we offer to our fellow patients and their loved ones, is to take lemons and make lemonade...
Events
fda2
GHLF/50-SN activity at FDA Arthritis Advisory Committee Meeting July 12th & July 13th

On July 12th and 13th the Arthritis Advisory Committee, or AAC, met at the FDA to participate in a hearing about two potential biosimilar drugs. GHLF provided commentary to speak on behalf of the 50-State Network. What is the AAC? The AAC, created by the FDA, reviews and evaluates data concerning the safety and efficacy […]

GHLF in the news
The New York Times logo
Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.

FDA Testimony
fda3-c
July 12th – GHLF testimony and recommendation to FDA on proposed biosimilar to HUMIRA (adalimumab)

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.